ClinicalTrialsFinder

Secondary Central Nervous System Lymphoma (SCNSL) Clinical Trials in Nanjing, Jiangsu

1 recruitingNanjing, Jiangsu, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520